Mr. Miguel Marti reports

AURORA URGES SHAREHOLDERS TO TAKE NO ACTION TO REVISED HOSTILE BID BY CURALEAF AS FORMAL REVIEW UNDERWAY

Aurora Cannabis Inc. responded today to a press release issued by Curaleaf Holdings Inc. regarding the filing of a notice of variation and change to revise its hostile takeover bid for all of the issued and outstanding common shares of the company to offer revised implied consideration of $5 (U.S.) per share, consisting of 0.4013 subordinate voting shares of Curaleaf plus $1 (U.S.) in cash per Aurora share.

"The filing of a revised hostile bid is simply the next step in the process, not a deadline to make a decision. Investors deserve the chance to review the revised hostile bid and decide for themselves whether it reflects the full value of the company they already own. Our board and special committee are commencing their review, and, until Aurora's formal recommendation is available, we urge investors to take no action," said Miguel Martin, executive chairman and chief executive officer of Aurora.

"Once the review is complete, the board will communicate its recommendation and provide the relevant information to shareholders to support them in considering their options," concluded Mr. Martin.

The company will provide a comprehensive response to Aurora shareholders in a timely manner once the special committee has completed its review and the board has made its recommendation with respect to the revised hostile bid.

Take no action

Aurora shareholders are advised to take no action on the hostile bid as previously recommended on Sept. 2, 2026, and to wait for further communication from the board of directors. Aurora shareholders will have until at least Dec. 4, 2026, to consider their options, being the revised expiry date of Curaleaf's hostile bid.

The special committee will consider the hostile bid with its advisers before making a recommendation to the board. Aurora shareholders will be notified of the board's formal recommendation through a news release and directors circular.

Shareholder assistance

Aurora shareholders with questions about the hostile bid or who would like to stay informed may contact Kingsdale Advisors, the company's strategic adviser and information agent.

Toll-free (within North America):  1-800-749-9052

Call or text:  416-623-4172

E-mail:  contactus@kingsdaleadvisors.com

Visit the Protect Aurora website.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands, including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corp. With world-class good-manufacturing-practice-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

Aurora's common shares trade on Nasdaq and the Toronto Stock Exchange under the symbol ACB.

Aurora has filed a solicitation/recommendation statement on Schedule 14D-9F with the U.S. Securities and Exchange Commission, which includes a directors circular, dated Sept. 1, 2026. Investors are urged to read this document and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, when they become available, before making any investment decision with respect to the hostile bid. The hostile bid is made for the securities of a Canadian issuer, and, while the hostile bid is subject to disclosure requirements of Canada, investors should be aware that these requirements are different from those of the United States. The enforcement by investors of civil liabilities under the U.S. federal securities laws may be affected adversely by the fact that the issuer is located in Canada, and that some or all of its officers and directors are residents of Canada.

We seek Safe Harbor.